Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Fritzwanker

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Molecules (Basel, Switzerland)|August 7, 2021
SR-17018 Stimulates Atypical µ-Opioid Receptor Phosphorylation and DephosphorylationSebastian Fritzwanker, Stefan Schulz, Andrea Kliewer
Communications Biology|April 15, 2023
In situ visualization of opioid and cannabinoid drug effects using phosphosite-specific GPCR antibodiesSebastian Fritzwanker, Falko Nagel, Andrea Kliewer, et al.
British Journal of Pharmacology|April 6, 2017
Targeting multiple opioid receptors - improved analgesics with reduced side effects?Thomas Günther, Pooja Dasgupta, Anika Mann, et al.
Pharmacology, Biochemistry, and Behavior|February 24, 2020
Analgesic treatment with buprenorphine should be adapted to the mouse strainJuliane Rudeck, Silvia Vogl, Céline Heinl, et al.
Communications Biology|September 15, 2021
HA-MOP knockin mice express the canonical µ-opioid receptor but lack detectable splice variantsSebastian Fritzwanker, Lionel Moulédous, Catherine Mollereau, et al.
Communications Biology|August 2, 2024
Key phosphorylation sites for robust β-arrestin2 binding at the MOR revisitedOwen Underwood, Sebastian Fritzwanker, Jaqueline Glenn, et al.
Communications Biology|November 9, 2022
A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screeningJohanna Kaufmann, Nina Kathleen Blum, Falko Nagel, et al.
Science Signaling|April 3, 2020
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonistsAlexander Gillis, Arisbel B Gondin, Andrea Kliewer, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Molecules (Basel, Switzerland)|August 7, 2021
SR-17018 Stimulates Atypical µ-Opioid Receptor Phosphorylation and DephosphorylationSebastian Fritzwanker, Stefan Schulz, Andrea Kliewer
Communications Biology|April 15, 2023
In situ visualization of opioid and cannabinoid drug effects using phosphosite-specific GPCR antibodiesSebastian Fritzwanker, Falko Nagel, Andrea Kliewer, et al.
British Journal of Pharmacology|April 6, 2017
Targeting multiple opioid receptors - improved analgesics with reduced side effects?Thomas Günther, Pooja Dasgupta, Anika Mann, et al.
Pharmacology, Biochemistry, and Behavior|February 24, 2020
Analgesic treatment with buprenorphine should be adapted to the mouse strainJuliane Rudeck, Silvia Vogl, Céline Heinl, et al.
Communications Biology|September 15, 2021
HA-MOP knockin mice express the canonical µ-opioid receptor but lack detectable splice variantsSebastian Fritzwanker, Lionel Moulédous, Catherine Mollereau, et al.
Communications Biology|August 2, 2024
Key phosphorylation sites for robust β-arrestin2 binding at the MOR revisitedOwen Underwood, Sebastian Fritzwanker, Jaqueline Glenn, et al.
Communications Biology|November 9, 2022
A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screeningJohanna Kaufmann, Nina Kathleen Blum, Falko Nagel, et al.
Science Signaling|April 3, 2020
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonistsAlexander Gillis, Arisbel B Gondin, Andrea Kliewer, et al.
Pageof 1